← Leaderboards
Aaron Scott Mansfield
Mayo Clinic Rochester
$1,664,916
Attributed
$3,266,326
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,266,326 · 3
By mechanism
UG1$1,821,528 · 1
R33$1,035,969 · 1
R21$408,829 · 1
Top collaborators
- Brian T. Cunningham3 shared
- Xing Wang3 shared
- Judy Caroline Boughey2 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Judy Caroline Boughey$6,732,851
- Lisa A. Schimmenti$3,629,699
- Paul D. Robbins$18,718,334
- Charles Lee Howe$6,719,913
- Manish Kohli$4,072,306
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsMonitorInnovationRecommendationTumor DnaMutationTissuesGenomicsPlasmaSpecimenDetectionRecurrenceGenesBloodMeasurementFda ApprovedTumorBiosensorClinically RelevantBiosensing TechniquesAssay DevelopmentClinical PracticeCostDesign
Grant awards (6)
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1 (funded extension)$934,827
UG1 · FY2025 · CA
Rapid, simple, and ultrasensitive quantitation of KRAS ctDNA at the point of care using CRISPR/Cas amplification and digital resolution biosensor microscopy$284,865
R33 · FY2025 · CA
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1$886,701
UG1 · FY2024 · CA
Rapid, simple, and ultrasensitive quantitation of KRAS ctDNA at the point of care using CRISPR/Cas amplification and digital resolution biosensor microscopy$359,637
R33 · FY2024 · CA
Rapid, simple, and ultrasensitive quantitation of KRAS ctDNA at the point of care using CRISPR/Cas amplification and digital resolution biosensor microscopy$391,467
R33 · FY2023 · CA
Blood-based biomarker of therapeutic efficacy for mesothelioma$408,829
R21 · FY2020 · CA · contact PI